Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

"Integrating the SBX technology into clinical and translational pipelines opens exciting new possibilities,” said Niall ...

Roche, hoping to carve out a standard-of-care spot for its PI3K inhibitor Itovebi, now has another leg to stand on with new ...

Roche's Itovebi combo gains EMA panel endorsement for advanced breast cancer with PIK3CA mutation. Read more here.

Roche raised the curtain on its novel approach to DNA sequencing earlier this year, and now it's working with the Broad ...

One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...

Tandem Diabetes Care has agreed to pay Roche Holding $36 million to settle a patent infringement claim. The two companies have granted each other licenses to patents on the insulin delivery systems in ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new ...

A group of advisers to the Food and Drug Administration said Roche Holding AG needs to study its blood cancer treatment in ...

The FDA has approved Roche’s Susvimo (ranibizumab injection) 100 mg/mL for treating patients with diabetic retinopathy (DR).

Roche Bermuda has awarded three $10,000 scholarships to graduating students at Bermuda College. A spokesperson said, “This ...

Roche (RHHBF) unit Genentech partners Orionis Biosciences to develop and commercialize cancer drugs in a deal that exceed $2B ...